Skip Navigation

Cardiovascular Research 2005 66(3):574-582; doi:10.1016/j.cardiores.2005.01.024
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kairuz, E. M.
Right arrow Articles by Woods, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kairuz, E. M.
Right arrow Articles by Woods, R. L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo

Evette M. Kairuza, Melissa N. Barbera,b, Colin R. Andersonc, Meetali Kanagasundarama, Grant R. Drummonda,b and Robyn L. Woodsa,*

aHoward Florey Institute, University of Melbourne, Victoria, 3010, Australia
bDepartment of Pharmacology, Monash University, Victoria, 3800, Australia
cDepartment of Anatomy and Cell Biology, University of Melbourne, Victoria 3010, Australia

* Corresponding author. Tel.: +61 3 83445264; fax: +61 3 93481707. Email address: r.woods{at}hfi.unimelb.edu.au

Objective: Elevated vascular plasminogen activator inhibitor-1 (PAI-1) levels are associated with atherosclerosis. In vitro, C-type natriuretic peptide (CNP) has anti-proliferative effects and inhibits the production of PAI-1 in cultured vascular cells. Whether CNP can affect PAI-1 in vivo, particularly in the setting of atherosclerosis, has not been reported.

Methods: Using the rabbit carotid arterial collar model of intimal hyperplasia (collar in place for 7 days), PAI-1 protein was compared in normal, vehicle (saline)-collared, and CNP-treated-collared arteries from the same animal. PAI-1 levels were measured by immunohistochemistry and densitometry and by Western blot. CNP was either infused into the peri-arterial space within one collar (10 fmol/h) or infused directly into the arterial lumen under one collar (100 pmol/h). In some rabbits (n=8), superoxide production in collared and normal artery segments was measured in vitro by chemiluminescence.

Results: PAI-1 was present throughout the vascular wall. Endothelial PAI-1 was elevated in saline-collared arteries (~16%, P<0.05; n=7 rabbits) compared with normal carotid segments. The collar induced both a neointima that contained PAI-1 and the accumulation of macrophages in the adventitia. Peri-arterial CNP reduced PAI-1 (P<0.05) in the endothelium (33%), adventitia (47%) and neointima (39%), compared with levels in the contralateral, saline-collared carotid artery, while macrophage infiltration was reduced. Elevated superoxide production in collared arteries was not altered by chronic in vivo treatment with CNP (n=8). Peri-arterial CNP treatment did not reduce intimal thickening. Intra-luminal CNP (n=6) reduced endothelial, neointimal and total vessel (Western blot) PAI-1, macrophage accumulation, and intimal thickening (all P<0.05).

Conclusions: CNP treatment of collared carotid arteries in vivo for 1 week suppressed endothelial and neointimal PAI-1, independently of intimal thickening. The CNP effects were not via superoxide. This is the first evidence that CNP inhibits activated PAI-1, in vivo.

KEYWORDS Restenosis; Intimal hyperplasia; Neointima; Atherosclerosis; Endothelium; Macrophages; Superoxide; NADPH oxidase


Time for primary review 27 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CirculationHome page
T. O. Peltonen, P. Taskinen, Y. Soini, J. Rysa, J. Ronkainen, P. Ohtonen, J. Satta, T. Juvonen, H. Ruskoaho, and H. Leskinen
Distinct Downregulation of C-Type Natriuretic Peptide System in Human Aortic Valve Stenosis
Circulation, September 11, 2007; 116(11): 1283 - 1289.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. N. Barber, M. Kanagasundaram, C. R. Anderson, L. M. Burrell, and R. L. Woods
Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia
Cardiovasc Res, July 1, 2006; 71(1): 179 - 188.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.